Analyst Ritu Baral of TD Cowen maintained a Buy rating on Krystal Biotech, retaining the price target of $202.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ritu Baral has given her Buy rating due to a combination of factors including Krystal Biotech’s strong financial performance and strategic initiatives. The company reported higher-than-expected Vyjuvek sales, reaching $97.8 million, which surpassed both internal and consensus estimates. This success is attributed to the expansion of the US sales force and the initiation of commercial sales in Germany.
Furthermore, Krystal Biotech’s reduction in non-GAAP operating expenses guidance and the high gross margin of 96% reflect efficient cost management and an optimized manufacturing process. The company’s robust cash position of $864 million and the expectation of continued revenue growth in the upcoming quarter further support the positive outlook. These elements collectively underpin Ritu Baral’s confidence in the company’s future performance, justifying the Buy rating.
According to TipRanks, Baral is a top 100 analyst with an average return of 34.9% and a 56.94% success rate. Baral covers the Healthcare sector, focusing on stocks such as Insmed, ACADIA Pharmaceuticals, and Alnylam Pharma.